Immunological Adaptations to Pregnancy in Women with Type 1 Diabetes by Groen, Bart et al.
  
 University of Groningen
Immunological Adaptations to Pregnancy in Women with Type 1 Diabetes
Groen, Bart; van der Wijk, Anne-Eva; van den Berg, Paul P.; Lefrandt, Joop D.; van den Berg,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Groen, B., van der Wijk, A-E., van den Berg, P. P., Lefrandt, J. D., van den Berg, G., Sollie, K. M., ... Faas,
M. M. (2015). Immunological Adaptations to Pregnancy in Women with Type 1 Diabetes. Scientific Reports,
5, [13618]. https://doi.org/10.1038/srep13618
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
1Scientific RepoRts | 5:13618 | DOi: 10.1038/srep13618
www.nature.com/scientificreports
Immunological Adaptations to 
Pregnancy in Women with Type 1 
Diabetes
Bart Groen1,2, Anne-Eva van der Wijk3, Paul P. van den Berg2, Joop D. Lefrandt4,  Gerrit van 
den Berg1, Krystina M. Sollie2, Paul de Vos3, Thera P. Links1 & Marijke M. Faas2,3
Despite adequate glycemic control, pregnancy outcome of women with type 1 diabetes (T1D) 
is still unfavorable as compared to healthy women. In a rat-model of T1D under normoglycemic 
conditions, adverse pregnancy outcome was also observed, which was associated with aberrant 
immunological adaptations to pregnancy. Because similar processes may occur in women with T1D 
we studied the systemic immune response in non-pregnant and pregnant women with and without 
T1D. The systemic immune response was assessed by using flow cytometry to evaluate the number 
and activational status of subpopulations of lymphocytes, Natural Killer cells and monocytes in 
peripheral blood of non-pregnant and pregnant women with and without T1D. An increased white 
blood cell count, an increased Th1/Th2 ratio, increased Natural Killer cell expression of CD335 and 
enhanced activation of intermediate and non-classical monocytes was observed in pregnant women 
with T1D vs. healthy pregnant women. Also, the pregnancy outcome (i.e. incidence of preterm 
delivery and macrosomia) of women with T1D was unfavorable as compared to healthy women. This 
study showed that in T1D, the immunological adaptations to pregnancy are disturbed. In addition 
to hyperglycemia, these different immunological adaptations may be responsible for the greater 
frequency of complications in pregnant women with T1D.
Despite tight glycemic control, frequent episodes of hyperglycemia still occur during pregnancy in type 
1 diabetic (T1D) patients1. Up to now, these hyperglycemic episodes have been thought to be responsi-
ble for the increased incidence of pregnancy complications2. However, recent work suggests that more 
factors may be involved3. We have shown that BBDP-rats, a rat-model of T1D, undergo aberrant immu-
nological adaptations during pregnancy, which are associated with pregnancy complications3. Similar 
events may occur in autoimmune T1D pregnant women.
Normal pregnancy is accompanied by various immunological adaptations facilitating implantation, 
placentation and tolerance of the semi-allogeneic fetus4–6; aberrations in these adaptations are associated 
with pregnancy complications, like miscarriages, preeclampsia and preterm delivery7–9. Normal systemic 
adaptations to pregnancy include a shift towards a type 2 immune response in T-lymphocytes4,10 and 
Natural Killer (NK) cells11,12 and an increased frequency of regulatory T-cells (Treg) during the first and 
second trimester of pregnancy10,11. Moreover, normal pregnancy is accompanied by a generalized activa-
tion of the inflammatory response, characterized by activation of monocytes and granulocytes, showing 
increased expression of various activation markers and altered cytokine production13,14. The proinflam-
matory condition of pregnancy is further supported by the fact that an increased amount of interme-
diate monocytes are found in pregnancy. Intermediate monocytes are a separate monocyte subset, a 
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transitional state between classical and non-classical monocytes, of which the function is not exactly 
known yet15. However, their numbers are increased in pro-inflammatory conditions, such as preeclamp-
sia and other inflammatory diseases15,16. It is unknown which immunological adaptations to pregnancy 
occur in women with autoimmune T1D.
The immune response in T1D patients is characterized by a type 1 immune response17, impaired func-
tion of regulatory T-lymphocytes18 and increased mRNA expression of interferon-gamma (IFN-γ )19, when 
compared to healthy individuals. In view of this different immune response in T1D women, we hypothe-
sized that pregnancy-induced immune adaptations differ between T1D and healthy pregnant women. The 
aim of this study was therefore to assess the systemic immunological adaptations to pregnancy in women 
with T1D. Understanding these aberrant changes may be a first step toward designing new means, in 
addition to glycemic control, for preventing pregnancy complications in T1D pregnant women.
Materials and Methods
Patients. This study was approved by and carried out in accordance with the guidelines of the ethic 
committees of the University Medical Center Groningen (UMCG) and Martini Hospital Groningen 
(NL30779.042.09) and registered at the Dutch trial register (NTR2195). All participants provided 
informed consent.
Four groups of women (age 18–40 years) were included in the study: healthy non-pregnant (n = 16), 
healthy pregnant (n = 19), non-pregnant with T1D (n = 19) and pregnant with T1D (n = 21). Healthy 
non-pregnant women were recruited from personnel at the UMCG and healthy pregnant women from 
the midwifery clinic. Non-pregnant and pregnant women with T1D were recruited from the diabe-
tes outpatient clinics of the UMCG and the Martini Hospital Groningen. Non-pregnant women filled 
in a questionnaire to obtain information about their cycle, contraception and last menstrual bleeding. 
Blood samples were obtained by venous punction into a 10 ml EDTA tube (BD-Plymouth, UK) from 
non-pregnant women within 10 days after the start of the last cycle and from pregnant women at 30 
weeks of gestation. All pregnant women were followed up during pregnancy and 6 weeks postpartum 
to evaluate pregnancy outcome. For the healthy pregnant women, exclusion criteria were gestational 
diabetes mellitus, known autoimmune, cardiovascular or other active diseases, > 2 previous miscar-
riages, maternal/fetal complications during pregnancy (i.e. preeclampsia/HELLP, intra-uterine growth 
restriction, prematurity, perinatal death, congenital malformations and neonatal death). For the healthy 
non-pregnant women, exclusion criteria were known active diseases. For both diabetic groups, exclusion 
criteria were HbA1c > 7.5% (at the time of sampling), renal failure (serum creatinine > 120 μ mol/l) and 
active treatment for autoimmune disease.
Outcome measures. The basic characteristics and pregnancy outcome variables are shown in Table 1.
Sample processing. Human blood leukocyte counts. 100 μ l of blood was used to measure total white 
blood cell numbers (WBC), using a microcell counter (Sysmex PocH 100i, Sysmex, Etten-Leur, The 
Netherlands).
Reagents. Washing buffer (phosphate-buffered saline (PBS) with 0.5% bovine serum albumin and 
0.1% NaN3), FACS-TM lysing buffer solution (BD Biosciences, Breda, the Netherlands), FoxP3-staining 
buffer set (eBioscience, Vienna, Austria) and complete RPMI-1640 medium (Lonza Benelux, Breda, the 
Netherlands) supplemented with 60 μ g/ml gentamycin (Invitrogen, Breda, the Netherlands).
Antibodies. We used antibody cocktails for T-lymphoyctes, NK cells. Unless stated otherwise, they were 
purchased from BioLegend (BioLegend Europe, Uithoorn, the Netherlands):
T-lymphocytes antibody cocktail. PerCP labeled anti-human CD3 (clone UCHT1), APC/Cy7 labeled 
anti-human CD4 (clone OKT4), PE/Cy7 labeled anti-human CD25 (clone BC96), Alexa Fluor 488 labe-
led anti-mouse/rat/human FOXP3 (clone 150D), Alexa Fluor 488 labeled mouse IgG1 isotype control 
(clone MOPC-21), PE labeled anti-mouse/human Tbet (clone eBio4B10, eBioscience, Germany), PE 
labeled mouse IgG1 isotype control (clone MOPC-21), Alexa Fluor 647 anti-mouse/human GATA-3 
(clone TWAJ, eBioscience) and Alexa Fluor 647 mouse IgG1 isotype control (MOPC-21).
Natural Killer cells antibody cocktail. PerCP labeled anti-human CD3 (clone UCHT1), APC labeled 
anti-human CD56 (clone MEM188), Pacific Blue labeled anti-human CD16 (clone eBioCB16, eBiosci-
ence) and PE labeled anti-human CD335 (clone 9E2), PE labeled mouse IgG1 isotype control (clone 
MOPC-21).
Monocytes antibody cocktail. PerCP/Cy5.5 labeled anti-human CD14 (clone HCD14), Pacific Blue labe-
led anti-human CD16 (clone eBioCB16, eBioscience), FITC labeled mouse anti-human HLA-DR, DP, 
DQ (i.e. MHC-II; clone Tu39, BD Pharmingen, Breda, Netherlands), PE labeled anti-human CD62L 
(clone DREG-56) and PE labeled mouse IgG1 isotype control (clone MOPC-21).
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Sample labeling. We used antibody cocktails for T-lymphocytes, NK-cells and monocytes. Immediately 
after sampling, whole blood was mixed with RPMI-1640 (1:1) and aliquoted, centrifuged and aspirated. 
Subsequently, all tubes were incubated with different antibody-cocktails in the dark for 30 min and 
washed with 500 μ l washing buffer, followed by red blood cells lysis with lysing buffer in the dark for 
30 minutes. After centrifugation, aspiration and washing, tubes for lymphocyte/lymphocyte isotype were 
incubated with fixperm (from FoxP3-staining buffer set) in the dark for 30 minutes. To the other tubes, 
300 μ l washing-buffer was added and stored. After 30 min incubation in the dark, tubes for lymphocyte 
and lymphocyte isotype staining were washed with perm (from FoxP3-staining buffer set) followed by 
incubation with the FoxP3, Tbet and GATA-3 antibodies or their isotype controls for 30 min in the dark 
at RT and washed with perm. Finally, 300 μ l washing buffer was added to these tubes. All tubes were 
stored in the dark at 4 °C until measurement by flow cytometry within 24hr.
Flow cytometry. Cells were analyzed using the BD LSR-II flow cytometer (BD Biosciences, Breda, 
the Netherlands). At least two hundred fifty thousand events were measured and saved. Analysis was 
performed using FlowJo 7.6.1 (Tree Star, Inc., Ashland, OR, USA).
Data analysis. Differential cell counts. First, different leukocyte populations (i.e. lymphocytes, mono-
cytes and granulocytes) were assessed, using a forward-/sideward scatterplot (FSC/SSC) of the tube 
stained for NK-cells. A gate was set around the leukocytes and secondary gates were set around the 
three different subpopulations in a new FSC/SSC plot (Fig. 1, panel A).
Basic characteristics
Type 1 diabetes  
NP (n = 19)
Type 1 diabetes  
P (n = 21) Healthy NP (n = 16) Healthy P (n = 19)
Age (yrs) 30.2 ± 1.2 28.8 ± 0.8 27.5 ± 1.2 29.6 ± 1.1
Body Mass Index (kg/m2) 24.2 (21.4–28.7) 23.7 (20.6–26.6) 21.8 (20.3–26.1) 22.5 (20.3–23.3)
Smoking (n) 3 (15.8%) 0 (0%) 1 (6.3%) 0 (0%)
Alcohol use (n) 12 (53.2%) 0 (0%)* 14 (87.5%) 0 (0%)*
Duration of diabetes 17.0 ± 2.0 15.2 ± 1.9 n/a n/a
Max. insulin dosage (IU/24 h) 50 ± 14 67 ± 31 n/a n/a
Mean HbA1c% (mmol/mol) 7.7 ± 0.2 (60 ± 2) 6.5 ± 0.1* (48 ± 1) n/a n/a
Proteinuria (n) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Nulliparous (n) 11 (57.9%) 12 (57.1%) 13 (81.3%) 12 (63.2%)
DA at sampling (wks) n/a 31 ± 2† n/a 30 ± 1
GA at delivery (wks) n/a 37 ± 1† n/a 40 ± 1
PE/HELLP (n) n/a 2 (9.5%) n/a 0 (0%)
Prematurity (n) n/a 5 (23.8%)† n/a 0 (0%)
Caesarean Section (n) n/a 6 (28.6%) n/a 2 (10.5%)
Perinatal Mortality (n) n/a 0 (0%) n/a 0 (0%)
Macrosomia (n) n/a 11 (52.4%)† n/a 1 (5.3%)
Birth weight n/a 3646 ± 126 n/a 3586 ± 88
Table 1.  Basic characteristics of the study groups. Values are shown as mean ± SEM, except for BMI, 
which was shown as median (Q1–Q3), and as numbers (percentage). NP: non-pregnant, P: pregnant, DA: 
duration of amenorrhea, GA: gestational age. Definitions of different outcome variables: ‘smoking’ (yes in 
case of smoking ≥ 1 cigarette/day and no in case of non-smokers or women who stopped smoking after a 
positive pregnancy test), ‘alcohol use’ (yes in case of drinking ≥ 1 unit/day and no in case of non-drinkers 
or women who stopped after a positive pregnancy test), Maximal dosage of insulin (IU) per 24 h at moment 
of sampling in type 1 diabetes NP and during pregnancy in type 1 diabetes P. ‘HbA1c’ (for non-pregnant 
women with diabetes: mean HbA1c of the last year; for pregnant women with diabetes: mean HbA1c 
during pregnancy), ‘proteinuria’ (yes in case of albuminuria > 16.0 mg/l at day of sampling for non-pregnant 
women and at beginning of pregnancy for pregnant women) ‘PE/HELLP’ (defined as previously described43), 
‘prematurity’ (delivery < 37 weeks of gestation), perinatal mortality (fetal loss < 20 weeks of gestation or 
neonatal loss during first 28 days after delivery) and macrosomia (birth weight > 90th percentile corrected 
for gestational age, sex and parity44). *Significantly different from the respective non-pregnant control, 
Independent T-test and Chi-square test, p < 0.05. †Significantly different from the respective pregnant 
control, Independent T-test and Chi-square test p < 0.05.
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Figure 1. For legend see next page.
Lymphocytes, NK cells and monocytes. The gating strategy of lymphocytes, NK-cells and monocytes was 
shown in Fig. 1, panels B–D respectively.
Examples of Mean Fluorescence Intensity (MFI) of monocyte MHC-II, CD62L and NK-cell CD335 
expression plots are shown in Fig. 2.
Statistics. Continuous parameters were expressed as mean ± SEM in case of normally distributed 
data, or as median (Q1–Q3) in case of skewed distribution. Independent T-tests and Chi-square-tests 
were used for categorical variables (corrected for multiple testing). Two-way ANOVA (with interaction 
effects) was used to analyze diabetes- and/or pregnancy-induced differences in immune cells. Before 
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performing this two-way ANOVA, normality of the data was tested using the Kolmogorov-Smirnov test. 
If data were distributed abnormally, log-transformation was used. For all analysis, p-values < 0.05 were 
considered as statistically significant and p-values between 0.05-0.1 were considered as a statistical trend. 
Statistical analyses were performed using SPSS for windows version 20.0.0.1 (SPSS, Inc., Chicago, IL).
Results
Basic characteristics. The mean age, BMI and smoking status were similar in all 4 groups (Table 1). 
Mean HbA1c was decreased in pregnant women with T1D as compared to non-pregnant women with 
T1D. In pregnant women with diabetes, we observed a significantly higher incidence of prematurity, 
macrosomia and preeclampsia (not significant) as compared to healthy women.
Peripheral immune response. WBC: T1D pregnant patients showed increased WBC-counts. WBC- 
count increased significantly in both diabetic and healthy women during pregnancy (Fig. 3A). However, 
WBC-count was significantly higher in diabetic pregnant women vs. healthy pregnant women (interac-
tion diabetes and pregnancy; p = 0.018). The number of lymphocytes did not change during pregnancy 
in women with T1D, whereas a decreased lymphocyte number was found in healthy pregnant woman 
vs. their non-pregnant controls (Fig. 3B). The number of monocytes and granulocytes was increased in 
both groups during pregnancy (Fig. 3C,D).
Lymphocytes: Increased Th1/Th2-ratio in pregnant women with T1D. The percentage of T-lymphocytes 
was similar in non-pregnant diabetic patients and healthy women (Fig.  4A). During pregnancy, the 
percentage of T-lymphocytes increased in healthy women only. The ratio of helper T- (Th) and cytotoxic 
T-cells (Tc) and the number of effector T-cells (Teff) cells were not affected by either diabetes or pregnancy 
(Fig. 4B,D). The percentage of CD4+ CD25- was lower, while the percentage of CD4+ CD25+ FoxP3+ 
cells was higher in non-pregnant diabetic vs. non-pregnant healthy women; these differences were not 
observed during pregnancy (Fig. 4C,E). The percentage of Tbet positive Th cells was significantly higher 
in both non-pregnant and pregnant diabetic women as compared to their respective healthy controls 
(Fig. 4F). The percentage of GATA-3 positive Th-cells was similar in the non-pregnant groups, while it 
was increased in healthy pregnant women only (Fig.  4G). This resulted in an increased Th1/Th2 ratio 
(p = 0.013) in pregnant women with diabetes vs. healthy pregnant controls (Fig. 4H).
NK-cells: Increased expression of the activating NK cell receptor NKp46 on NK-cell subsets in pregnant 
women with T1D. The percentage of total NK-cells was lower in pregnant and non-pregnant women 
with diabetes than in the respective healthy controls (Fig. 5A). A trend towards a decreased ratio of cyto-
toxic NK- (ctNK) and cytokine secreting NK-cells (csNK) was observed in non-pregnant women with 
T1D as compared to healthy non-pregnant women (Fig. 5B). During pregnancy, this ratio decreased in 
Figure 1. The gating strategy of T-lymphocytes, NK-cells and monocytes. [Panel-A]: First a FSC/SSC-
plot was made and we gated all leukocytes (A1). Leukocytes were copied to a new scatterplot identifying 
lymphocytes (including NK-cells), monocytes and granulocytes (A2). [Panel-B]: The lymphocyte population 
was copied to a SSC/CD3-scatterplot identifying T-cells (CD3+ ) (B1). The T-cell gate was copied to a CD3/
CD4-scatterplot identifying Th-cells (CD3+ /CD4+ ) and Tc-cells (CD3+ /CD4-) (B2). To identify CD25+ 
cells (Teff and Treg), we used CD3-cells (i.e. B-cells, which are CD25-negative), to set the gate. Therefore, 
the CD3- cells were copied to a CD25/CD3-scatterplot and a gate was set in such a way that CD3-cells were 
> 99% negative for CD25 (B3). This gate was copied to a new CD25/CD3-scatterplot in which we copied the 
Th-cells (B4). Teff-cells were defined as CD25+ (B4). The Th-cell gate was copied to a CD4/Tbet-scatterplot 
identifying type 1 Th-cells (Th1) (B5-6)). We used the isotype for Tbet to define Tbet+ cells. Therefore, 
in the isotype-control, gates for Tbet were set in such a way that the positive gate contained no more than 
1% of the population (B5). This gate was copied to the sample containing the Tbet-antibody calculating 
percentage of Tbet + Th-cells. Similar gating procedures with isotype controls were used identifying Th2 
(CD3+ /CD4+ /GATA-3+ ) and Treg (Cd3+ /CD4+ /CD25+ /FoxP3+ ). [Panel-C]: To identify NK-cells, 
lymphocytes were copied to a CD3/CD56-plot and a gate was set around the CD3− /CD56+ cells and 
around CD3+ /CD56+ cells identifying total NK-cell and NKT-cell populations, respectively (C1). The NK-
cell gate was copied to a CD56/CD16-scatterplot (C2). CD56dimCD16+ cells were defined as cytotoxic 
NK (ctNK) cells and CD56brightCD16+ /− as cytokine-secreting NK-cells (csNK). To identify expression 
of CD335 on ctNK-cells, isotype was used as described before (C3-4). Similarly, the CD335-expression on 
csNK-cells was evaluated. [Panel D]: To identify monocytes subsets and activation status, monocytes were 
copied to a CD14/CD16-plot. Monocytes were divided into three populations, i.e. 1) classical monocytes 
(CD14+ + /CD16− ), 2) intermediate monocytes (CD14+ + /CD16+ ) and 3) nonclassical monocytes 
(CD14+ /CD16+ ) (D1). To evaluate the activation status of these monocyte subsets, we used MHC-II and 
CD62L. We used isotypes for MHC-II and CD62L as described before (example of CD62L-expression of 
classical monocytes in panel D2–3).
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healthy women and tended to decrease in diabetic women. The percentage of NKT-cells was influenced 
neither by pregnancy nor diabetes (Fig. 5C).
To show functional changes of NK cells, we studied the expression of the activating receptor NKp46 
(CD335). We choose to study this receptor, since studies have shown that the expression of NKp46 may 
not only be associated with diabetes development20, but also with infertility21 and preeclampsia22.
Most of the ctNK-cells were positive for CD335 (> 80%). The percentage of positive cells and the MFI 
of CD335 for ctNK-cells was significantly higher in non-pregnant diabetic women than in non-pregnant 
healthy women (Fig.  5D,E). During normal pregnancy, both the numbers and the MFI of CD335+ 
ctNK-cells increased as compared to non-pregnant controls. In T1D, we only observed a trend towards 
an increased MFI of CD335.
Almost all csNK-cells expressed CD335; the percentage of positive cells was not affected by diabetes 
or pregnancy (Fig.  5F). The MFI of CD335 on csNK-cells was similar in both non-pregnant groups 
(Fig.  5G). However, we observed an increased (trend) MFI in pregnant diabetic women as compared 
to non-pregnant diabetic women. This resulted in a significantly increased MFI of CD335 in pregnant 
women with T1D vs. healthy pregnant women.
Monocytes: Increased activation of intermediate and non-classical monocytes in pregnant women with 
T1D. The percentage of intermediate monocytes was decreased in non-pregnant women with diabetes 
as compared to healthy non-pregnant women, while percentages of classical and non-classical monocytes 
did not differ between these 2 groups (Fig.  6A–C). In healthy pregnant women we found a decreased 
percentage of classical monocytes and an increased percentage of intermediate monocytes vs. healthy 
Figure 2. Mean Fluorescent Intensity (MFI) of monocyte MHC II (panel A), monocyte CD62L (panel B) 
and NK cell CD335 (panel C) expression. The left graph in each panel represents the MFI of the isotype 
control (which was similar for all subtypes). Subpopulations were gated using the gating strategy of Fig. 1. 
Gates were set in the isotype control in such a way that < 1% of the cells stained for the isotype control 
were positive (percentage positive cells are shown in the graphs). This gate was then copied to the samples 
containing the antibodies.
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non-pregnant women. In women with diabetes, only an increased percentage of intermediate monocytes 
was found during pregnancy as compared with non-pregnant women.
In all groups of women, the three monocyte subsets were 100% positive for MHC-II (data not shown); 
however, the MFI of MHC-II differed between the subsets (being lowest in classical monocytes and high-
est in intermediate monocytes) and was affected by diabetes and pregnancy (Fig. 6D–L). In non-pregnant 
diabetic women, the MFI of MHC-II of classical and intermediate subsets was significantly lower as 
compared with healthy non-pregnant controls. In healthy pregnant women, MFI of MHC-II of classical 
and intermediate monocytes significantly decreased as compared to non-pregnant women. In contrast, 
in pregnant women with T1D, MFI of MHC-II significantly increased in intermediate and non-classical 
monocytes, resulting in an increased MFI of MHC-II of intermediate and non-classical monocytes in 
pregnant women with T1D vs. healthy pregnant women.
In all four groups, almost all classical monocytes were positive for CD62L. This was not the case for 
the intermediate and non-classical subsets. In these subsets the percentage of CD62L positive monocytes 
was higher in non-pregnant women with diabetes vs. healthy non-pregnant controls, while the opposite 
was observed during pregnancy (interaction pregnancy and diabetes; p = 0.00006 and p = 0.0003). In 
non-pregnant women, the MFI of CD62L on classical monocytes was not affected by diabetes, while this 
MFI was increased in intermediate monocytes and decreased in non-classical monocytes in women with 
diabetes as compared with healthy women. During healthy pregnancy, MFI of CD62L was not affected 
in classical and intermediate monocytes, but was decreased in non-classical monocytes. By contrast, MFI 
of CD62L was decreased in all monocyte subsets during a diabetic pregnancy.
Discussion
This is the first study showing differences in the systemic immune response in pregnant women with 
T1D as compared with healthy pregnant women. The strength of our study is that we evaluated various 
subpopulations of immune cells, of the specific and the innate arm, and their activation status, giving 
us a broad overview of changes in different cells populations. Our data showed that pregnant women 
with T1D have an increased WBC-count, Th1/Th2 ratio, and expression of NKp46 on NK-cells and 
enhanced activation of intermediate and non-classical monocytes as compared to healthy controls. The 
exact mechanisms are unclear and probably multifactorial. The immunological adaptations in normal 
pregnancy are suggested to be driven by factors such as increased sex hormone concentrations23, pres-
ence of the placenta24 and the production of factors by the placenta, like placental microparticles or 
Figure 3. WBC (A), lymphocytes (B), monocytes (C) and granulocytes (D) in non-pregnant (NP) and 
pregnant (P) women with type 1 diabetes (dotted line) and healthy women (continuous line). *Significant 
difference between the marked groups, independent T-test, p < 0.05. I: Significant interaction between 
diabetes and pregnancy, p < 0.05, two-way ANOVA.
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Figure 4. The percentage of T-lymphocytes (A), ratio of helper (Th) and cytotoxic (Tc) T-cells (B), 
percentage of naive T-cells (C), effector T-cells (D), regulatory T-cells (Treg) (E), Tbet positive Th (as a 
transcription factor for Th1) (F), GATA-3 positive Th (as a transcription factor for Th2) (G) and the ratio 
Th1/Th2 (H) in non-pregnant (NP) and pregnant (P) women with type 1 diabetes and healthy women. 
*Significant difference between the marked groups, independent T-test, p < 0.05. I: Significant interaction 
between diabetes and pregnancy, p < 0.05, two-way ANOVA.
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cytokines25. Aberrant adaptations in diabetic pregnancy may be due to changes in either of these factors. 
Alternatively, it may also be due to the presence of autoimmune disease, inducing differences in immune 
cells, resulting in a different response to pregnancy factors.
It is well known that the immune response of non-pregnant diabetic patients differs from that of 
healthy subjects17–19,26,27. Our data confirmed an increased Th1 response and an increased activation 
status of monocytes in diabetic women vs. healthy women26–28. Moreover, we augment previous knowl-
edge by showing that only intermediate and non-classical monocytes are activated. We also showed an 
increased percentage of Treg in non-pregnant diabetic women, which may act as a compensatory mech-
anism for impaired Treg function18. Moreover, we found decreased NK-cell numbers in non-pregnant 
diabetic women, which may be related to this defective Treg function29. CD335 (or NKp46) , a member 
of the cytotoxicity receptor-family30, is essential in the development of T1D20. This may explain why this 
receptor is upregulated on ctNK-cells in non-pregnant diabetic women.
Various studies observed a decreased Th1/Th2 ratio during healthy pregnancy4,10. Although we did not 
find this, we observed an increase in GATA-3 positive Th lymphocytes in healthy pregnant women. The 
reason for this discrepancy is not clear, but may be due to methodological differences31. The decreased 
percentage of Treg during pregnancy is in line with earlier reports32,33. This decrease in Treg appeared 
to be more pronounced in diabetic women, suggesting that Treg do adapt to a diabetic pregnancy. The 
increase in Th1 response in diabetic pregnancy was also found in non-pregnant diabetic women, suggest-
ing that this is due to the diabetic state. We observed an increased Th1/Th2 ratio in diabetic pregnancy. 
As such an increased ratio is associated with pregnancy complications, such as preeclampsia and mis-
carriage7,10, it may be suggested that the increased Th1/Th2 ratio in diabetic pregnancy is be involved in 
the increased numbers of pregnancy complications in this condition.
Figure 5. The percentage of total NK-cells (A), ratio of cytotoxic (ct)NK-cells and cytokine secreting (cs)
NK-cells (B), NKT-cells (C), the percentages and the mean fluorescence intensity (MFI) of CD335 on ctNK 
(D,E) and csNK-cells (F,G) in non-pregnant (NP) and pregnant (P) women with type 1 diabetes and healthy 
women. *Significant difference between the marked groups, independent T-test, p < 0.05.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:13618 | DOi: 10.1038/srep13618
In contrast to other studies, pregnancy did not affect the total percentage of NK-cells in healthy 
controls11,34. However, in line with former studies, the absolute numbers of NK-cells tended to decrease 
in healthy pregnancy (1.73·108 vs. 1.28·108, p = 0.053), but not in T1D pregnancy (1.21·108 vs. 1.12·108, 
p = 0.652). This may be due to the already low frequency of these cells in non-pregnant diabetic women; 
a further decrease may not be required during pregnancy. We observed increased CD335 expression on 
Figure 6. The percentage of classical, intermediate and non-classical monocytes (A–C), MFI of MHC-II 
of the three subsets (D–F), and percentage and MFI of CD62L positive monocyte subsets (G–L) in non-
pregnant (NP) and pregnant (P) women with type 1 diabetes and healthy women. *Significant difference 
between the marked groups, independent T-test, p < 0.05. I: Significant interaction between diabetes and 
pregnancy, p < 0.05, two-way ANOVA.
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both NK-cell subpopulations in pregnant women with diabetes. The expression of CD335 (or NKp46) is 
negatively correlated between csNK cell CD335 expression and type 1 cytokines, such as TNF-α 21,35 in 
a fertile population, but not in women with recurrent pregnancy loss or implantation failure21. This may 
suggest that signal transduction via CD335 on NK cells is changed in these pregnancy complications. If 
this is also the case in diabetic pregnancy, upregulation of CD335 may be a compensatory mechanisms.
We found increased expression of MHC-II and decreased expression of CD62L on intermediate mono-
cytes in diabetic pregnant women, suggesting activation of these cells. Decreased MHC-II expression on 
monocytes is associated with inadequate presentation of antigens to T-cells and disturbed T-cell stimula-
tion36. Thus, the ability of these monocytes to present antigens to T-cells is increased in pregnant women 
with diabetes, which could lead to enhanced activation of the systemic immune response. Shedding of 
CD62L is usually associated with the activation of monocytes37, indicating that the monocytes of diabetic 
women may be further activated during pregnancy. Intermediate monocytes have been suggested to play 
a role in the pathophysiology of preeclampsia16,38. It may therefore be suggested that increased activation 
of intermediate monocytes during diabetic pregnancy, may be involved in the increased incidence of 
preeclampsia in these women.
Our observations of aberrant immunological changes in diabetic pregnancy raise further questions. 
Various adaptations of the immune response are required for adequate implantation, placentation and 
tolerance of the semi-allogeneic fetus4–6. We hypothesize that the increased pregnancy complications 
in diabetic pregnancy are partly the result of the disturbed immunological adaptations, immunologi-
cal maladaptations may lead to pregnancy complications7–9. We cannot completely rule out a role for 
hyperglycemia, since, although the mean HbA1c was significant decreased in pregnant T1D women as 
compared to non-pregnant T1D women (which is most likely the result of the preconceptional care of 
these women39), it is still increased as compared to healthy pregnant women (mean HbA1c 4.7% for 
healthy pregnant women with a gestational age of 30 weeks40). However, our suggestion of immunologi-
cal involvement is corroborated by our findings in an animal model for T1D, in. In this model, in the face 
of normoglycemia, similar immunological maladaptations as in the present study, were associated with 
increased pregnancy complications3. Our hypothesis is further endorsed by the fact that in the present 
study women with T1D and complicated pregnancy outcome (i.e. preeclampsia or preterm delivery) 
showed even higher Th1/Th2-ratios and more pronounced activation of monocytes as compared to dia-
betic women with normal pregnancy outcome (data not shown). Moreover, our suggestion that disturbed 
immunological adaptations in an autoimmune environment contributes to pregnancy complications is 
in line with findings in other autoimmune diseases, such as rheumatoid arthritis or systemic lupus ery-
thematosus41,42. Unfortunately, due to the relatively small sample size in this study, we were not able to 
correlate immunological parameters to pregnancy outcome parameters.
In conclusion, this study showed that in T1D the pregnancy induced immunological adaptations are 
disturbed. Importantly, these different immunological adaptations may be responsible, as also shown for 
other autoimmune diseases, for the increased frequency of complications in pregnant women with T1D. 
Further mechanistical insights into the role of various immune cells in implantation as well as placental 
and fetal development in healthy and diabetic pregnancy are warranted and may lead to new therapeutic 
approaches to improve pregnancy outcome of women with T1D.
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